Revised Disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Cadila Healthcare Ltd has submitted the revised disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 199204-03-2015
04-03-2015
Disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Cadila Healthcare Ltd has submitted the disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 199203-03-2015
Disclosures under Reg.13(4) of SEBI (Prohibition of Insider Trading) Regulations, 1992
N R Desai (HUF) has submitted the disclosures under Reg.13(4) of SEBI (Prohibition of Insider Trading) Regulations, 199203-03-2015
Disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Cadila Healthcare Ltd has submitted the disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 199202-03-2015
Disclosures under Reg.13(4) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Nitin R Desai (HUF) & Nitin R Desai has submitted the disclosures under Reg.13(4) of SEBI (Prohibition of Insider Trading) Regulations, 199202-03-2015
Disclosures under Reg.13(4) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Nitin R Desai has submitted the disclosures under Reg.13(4) of SEBI (Prohibition of Insider Trading) Regulations, 199228-02-2015
Investor Presentaiton
Cadila Healthcare Ltd has submitted to BSE a copy of Presentation, proposed to be made to the investors at the Investors' Conference at Mumbai on February 24, 2015 to bring to the notice of members of exchange and investors at large.23-02-2015
Zydus completes single rising dose Phase I studies for its oral HIF inhibitor, ZYAN1 for treating Anemia and initiates multiple dosing studies
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated February 16, 2015 titled "Zydus completes single rising dose Phase I studies for its oral HIF inhibitor, ZYAN1 for treating Anemia and initiates multiple dosing studies".16-02-2015
Results Press Release
Cadila Healthcare Ltd has submitted to BSE a copy of Results Press Release for the period ended December 31, 2014.10-02-2015
Announces Q3 results & Limited Review Report for the Quarter ended December 31, 2014
Cadila Healthcare Ltd has announced the following results for the quarter ended December 31, 2014:The Unaudited Standalone results for the Quarter ended December 31, 2014The Company has posted a net profit of Rs. 3611.60 million for the quarter ended December 31, 2014 as compared to Rs. 1949.30 million for the quarter ended December 31, 2013. Total Income has increased from Rs. 10874.80 million for the quarter ended December 31, 2013...10-02-2015